NSE:GLAXO (India)
Â
Shs Dematerialised
₹
2,838.8
+38.9 (+1.39%)
Sep 18
Business Description
GlaxoSmithKline Pharmaceuticals Ltd
SIC : 2834
ISIN : INE159A01016
Share Class Description:
NSE:GLAXO: Shs DematerialisedTotal Employee Number:
3,103Compare
Compare
Traded in other countries / regions
500660.India Index Membership
NIFTY 500 IPO Date
2000-12-15Description
GlaxoSmithKline Pharmaceuticals Ltd is the Indian listed subsidiary of the GSK group, engaged in manufacturing, distributing and marketing pharmaceuticals and vaccines in India. Its portfolio spans general medicines such as anti-infectives, pain management, vitamins, minerals, nutritionals, hormones and dermatologicals, along with vaccines for children and adults and specialty medicines for respiratory and oncology. Key brands include Augmentin, Calpol, Ceftum, Betnovate, Neosporin, Tenovate, Physiogel and Flutivate. The company sells primarily to hospitals, doctors, pharmacies and distributors across India, with a smaller presence outside India, and derives the majority of its revenue from the domestic market. It operates as a single reportable segment and generates revenue mainly through the sale of its pharmaceutical and vaccine products.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 82.84 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.02 | |||||
Interest Coverage | 392.3 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 17 | |||||
Beneish M-Score | -2.46 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.7 | |||||
3-Year EBITDA Growth Rate | 17.7 | |||||
3-Year EPS without NRI Growth Rate | 18.7 | |||||
3-Year FCF Growth Rate | 24.4 | |||||
3-Year Book Growth Rate | 9.2 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.49 | |||||
9-Day RSI | 44.07 | |||||
14-Day RSI | 49.13 | |||||
3-1 Month Momentum % | 26.97 | |||||
6-1 Month Momentum % | 18.04 | |||||
12-1 Month Momentum % | 4.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.03 | |||||
Quick Ratio | 1.77 | |||||
Cash Ratio | 1.55 | |||||
Days Inventory | 129.01 | |||||
Days Sales Outstanding | 27.65 | |||||
Days Payable | 153.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.01 | |||||
Dividend Payout Ratio | 0.92 | |||||
3-Year Dividend Growth Rate | 11.9 | |||||
Forward Dividend Yield % | 2.01 | |||||
5-Year Yield-on-Cost % | 3.54 | |||||
Shareholder Yield % | 1.96 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 64.82 | |||||
Operating Margin % | 32.54 | |||||
Net Margin % | 27.01 | |||||
EBITDA Margin % | 38.42 | |||||
FCF Margin % | 24.38 | |||||
OCF Margin % | 25.78 | |||||
ROE % | 54.07 | |||||
ROA % | 26.49 | |||||
ROIC % | 77.43 | |||||
3-Year ROIIC % | -633.77 | |||||
ROC (Joel Greenblatt) % | 490.24 | |||||
ROCE % | 64.67 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 45.16 | |||||
Forward PE Ratio | 41.43 | |||||
PE Ratio without NRI | 45.91 | |||||
Shiller PE Ratio | 58.38 | |||||
Price-to-Owner-Earnings | 49.26 | |||||
PEG Ratio | 2.3 | |||||
PS Ratio | 12.2 | |||||
PB Ratio | 21.28 | |||||
Price-to-Tangible-Book | 21.34 | |||||
Price-to-Free-Cash-Flow | 56.89 | |||||
Price-to-Operating-Cash-Flow | 53.4 | |||||
EV-to-EBIT | 31.38 | |||||
EV-to-EBITDA | 29.99 | |||||
EV-to-Revenue | 11.52 | |||||
EV-to-FCF | 53.47 | |||||
Price-to-GF-Value | 1.04 | |||||
Price-to-Projected-FCF | 4.37 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.56 | |||||
Price-to-Graham-Number | 6.7 | |||||
| Price-to-Net-Current-Asset-Value | 31.11 | |||||
| Price-to-Net-Cash | 68.94 | |||||
Earnings Yield (Greenblatt) % | 3.18 | |||||
FCF Yield % | 1.75 | |||||
Forward Rate of Return (Yacktman) % | 21.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GlaxoSmithKline Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 39,549.4 | ||
| EPS (TTM) (₹) | 63.053 | ||
| Beta | 0.7073 | ||
| 3-Year Sharpe Ratio | 0.69 | ||
| 3-Year Sortino Ratio | 1.34 | ||
| Volatility % | 26.21 | ||
| 14-Day RSI | 49.13 | ||
| 14-Day ATR (₹) | 87.874648 | ||
| 20-Day SMA (₹) | 2932.91 | ||
| 12-1 Month Momentum % | 4.43 | ||
| 52-Week Range (₹) | 2088.1 - 3120.7 | ||
| Shares Outstanding (Mil) | 169.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GlaxoSmithKline Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GlaxoSmithKline Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 57.000000 Cash Dividend | 2026-05-29 | 2,296.20 (+0.05%) | ||
| INR 42.000000 Cash Dividend | 2025-05-30 | 3,263.40 (-2.18%) | ||
| INR 12.000000 Cash Dividend | 2024-11-07 | 2,629.60 (+1.08%) | ||
| 2:1 Stock Split | 2018-09-11 | 1,795.05 (+2.65%) |
Show
Entries
GlaxoSmithKline Pharmaceuticals Ltd Frequently Asked Questions
What is GlaxoSmithKline Pharmaceuticals Ltd(NSE:GLAXO)'s stock price today?
The current price of NSE:GLAXO is ₹2838.80. The 52 week high of NSE:GLAXO is ₹3120.70 and 52 week low is ₹2088.10.
When is next earnings date of GlaxoSmithKline Pharmaceuticals Ltd(NSE:GLAXO)?
The next earnings date of GlaxoSmithKline Pharmaceuticals Ltd(NSE:GLAXO) is .
Does GlaxoSmithKline Pharmaceuticals Ltd(NSE:GLAXO) pay dividends? If so, how much?
The Dividend Yield %  of GlaxoSmithKline Pharmaceuticals Ltd(NSE:GLAXO) is 2.01% (As of Today), Highest Dividend Payout Ratio of GlaxoSmithKline Pharmaceuticals Ltd(NSE:GLAXO) was 1.38. The lowest was 0.59. And the median was 0.75. The  Forward Dividend Yield % of GlaxoSmithKline Pharmaceuticals Ltd(NSE:GLAXO) is 2.01%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers